FOLLOW THE CONNECTIONS

The knowledge graph.

Explore substances, mechanisms, and effects. Select a node to read its article and inspect the evidence.

Mapping connections…

SubstanceConceptRelationship
Explore an accessible text view

Substances

Concepts

Relationships

  • Editorial index: substances classified under stimulant. This index does not assert a combined effect. Compounds associated with increased arousal; mechanisms and risks differ.

    Source 1 ↗Source 2 ↗
  • Editorial index: substances classified under methylxanthine. This index does not assert a combined effect. A chemical family that includes caffeine.

    Source 1 ↗
  • Editorial index: substances classified under amino acid derivative. This index does not assert a combined effect. A chemical grouping, not a shared claim of cognitive benefit.

    Source 1 ↗Source 2 ↗
  • Editorial index: substances classified under hormone. This index does not assert a combined effect. Endogenous signals that can also be administered as products.

    Source 1 ↗
  • Editorial index: substances classified under psychedelic. This index does not assert a combined effect. Compounds that can produce substantial changes in perception and experience.

    Source 1 ↗
  • Editorial index: substances classified under adenosine antagonist. This index does not assert a combined effect. Blocks adenosine receptor signaling.

    Source 1 ↗
  • Editorial index: substances classified under nicotinic agonist. This index does not assert a combined effect. Activates nicotinic acetylcholine receptors.

    Source 1 ↗
  • Editorial index: substances classified under serotonin 5-ht2a receptor. This index does not assert a combined effect. A serotonin receptor implicated by human antagonist experiments in acute psilocybin effects.

    Source 1 ↗
  • Editorial index: substances classified under energy buffering. This index does not assert a combined effect. Supports the creatine–phosphocreatine system in tissue energy metabolism.

    Source 1 ↗
  • Editorial index: substances classified under circadian signaling. This index does not assert a combined effect. Signals associated with the timing of sleep and waking.

    Source 1 ↗
  • Editorial index: substances classified under adenosine. This index does not assert a combined effect. A neuromodulator involved in sleep pressure and arousal.

    Source 1 ↗
  • Editorial index: substances classified under acetylcholine. This index does not assert a combined effect. The endogenous transmitter at nicotinic and muscarinic receptors.

    Source 1 ↗
  • Editorial index: substances classified under serotonin. This index does not assert a combined effect. A transmitter with multiple receptor families; receptor activity is not a benefit score.

    Source 1 ↗
  • Editorial index: substances classified under cyp1a2. This index does not assert a combined effect. A liver enzyme important in caffeine metabolism; activity varies with exposures and physiology.

    Source 1 ↗
  • Editorial index: substances classified under cyp2a6. This index does not assert a combined effect. An enzyme with an important role in nicotine metabolism.

    Source 1 ↗
  • Editorial index: substances classified under attention. This index does not assert a combined effect. Performance on tasks that test selecting or switching attention. A task result does not measure general intelligence or subjective focus.

    Source 1 ↗
  • Editorial index: substances classified under sleep. This index does not assert a combined effect. Measured sleep outcomes, such as onset time and continuity. Direction and clinical meaning depend on the endpoint and population.

    Source 1 ↗Source 2 ↗
  • Editorial index: substances classified under exercise performance. This index does not assert a combined effect. Performance outcomes during exercise or training.

    Source 1 ↗
  • Editorial index: substances classified under altered perception. This index does not assert a combined effect. Changes in the character of sensory experience.

    Source 1 ↗
  • Editorial index: substances classified under us federal schedule i. This index does not assert a combined effect. A US federal classification; not a worldwide or state-level legal conclusion.

    Source 1 ↗
  • Editorial index: substances classified under adenosine receptors. This index does not assert a combined effect. Receptors activated by adenosine; caffeine antagonism changes signaling without removing the physiological need for sleep.

    Source 1 ↗
  • Editorial index: substances classified under nicotinic acetylcholine receptors. This index does not assert a combined effect. Ligand-gated receptors activated by acetylcholine and nicotine. Receptor subtypes and desensitization affect the response.

    Source 1 ↗
  • Editorial index: substances classified under tobacco-smoke exposure. This index does not assert a combined effect. Smoke exposure can induce CYP1A2 activity. This context is distinct from nicotine exposure and from the route of caffeine administration.

    Source 1 ↗
  • Editorial index: substances classified under subjective alertness. This index does not assert a combined effect. A reported sense of being awake and responsive. It can change independently of objective task performance or later sleep.

    Source 1 ↗
  • Editorial index: substances classified under anxiety and jitteriness. This index does not assert a combined effect. Uncomfortable arousal or unease reported after exposure. The experience depends on dose, sensitivity and context.

    Source 1 ↗
  • Editorial index: substances classified under craving. This index does not assert a combined effect. An urge to use a substance; with nicotine dependence it may appear during abstinence and be temporarily relieved by renewed exposure.

    Source 1 ↗
  • Editorial index: substances classified under daytime sleepiness. This index does not assert a combined effect. A reported tendency to feel sleepy during waking hours. Adverse-event reporting is distinct from an objective sleep-latency test.

    Source 1 ↗
  • Editorial index: substances classified under muscle creatine stores. This index does not assert a combined effect. The measured concentration of total creatine in skeletal muscle. Tissue concentration is a biochemical outcome, not a subjective benefit score.

    Source 1 ↗
  • Editorial index: substances classified under depression symptom severity. This index does not assert a combined effect. Severity measured with a specified clinical instrument, population and follow-up interval; a scale change does not by itself establish remission.

    Source 1 ↗
  • Editorial index: substances classified under behavioral sleep–wake scheduling. This index does not assert a combined effect. Scheduled sleep and waking behavior used alongside a study treatment. Combined-treatment findings should retain this context.

    Source 1 ↗
  • Editorial index: substances classified under clinical psychological support. This index does not assert a combined effect. Preparation and support supplied within a clinical research protocol. Findings from that setting do not establish outcomes of unsupervised exposure.

    Source 1 ↗
  • Editorial index: substances classified under histamine. This index does not assert a combined effect. A signaling molecule acting at histamine receptors; effects depend on receptor and tissue.

    Source 1 ↗
  • Editorial index: substances classified under histamine h1 receptor. This index does not assert a combined effect. A histamine receptor targeted by H1 antihistamines; distinguish it from muscarinic receptor activity.

    Source 1 ↗
  • Editorial index: substances classified under muscarinic acetylcholine receptors. This index does not assert a combined effect. An acetylcholine receptor family distinct from nicotinic receptors. Antagonism can reduce secretions and produce other anticholinergic effects.

    Source 1 ↗
  • Editorial index: substances classified under dopamine transporter. This index does not assert a combined effect. A membrane transporter involved in dopamine reuptake. Human PET studies can measure occupancy without establishing general cognitive benefit.

    Source 1 ↗Source 2 ↗
  • Editorial index: substances classified under dopamine. This index does not assert a combined effect. A neurotransmitter whose extracellular availability is influenced by dopamine transporters. Increased signaling is not a universal benefit.

    Source 1 ↗
  • Editorial index: substances classified under wakefulness. This index does not assert a combined effect. The experience of being awake rather than sleepy. Reported wakefulness is distinct from performance and measured ability to remain awake.

    Source 1 ↗
  • Editorial index: substances classified under drowsiness. This index does not assert a combined effect. A subjective tendency toward sleep. Reports of drowsiness and laboratory performance can diverge.

    Source 1 ↗Source 2 ↗
  • Editorial index: substances classified under episodic memory. This index does not assert a combined effect. Memory for associations and events, operationalized here through a specified cognitive test rather than a general memory score.

    Source 1 ↗
  • Editorial index: substances classified under measured wakefulness. This index does not assert a combined effect. Sleep latency or wake-maintenance measurements under defined laboratory conditions; not interchangeable with subjective alertness.

    Source 1 ↗
  • Editorial index: substances classified under stroke recovery. This index does not assert a combined effect. Functional and neurological recovery after stroke, measured using specified clinical scales and follow-up.

    Source 1 ↗
  • Editorial index: substances classified under antihistamine. This index does not assert a combined effect. Compounds that inhibit histamine receptor signaling. Receptor selectivity and additional actions differ across drugs.

    Source 1 ↗
  • Editorial index: substances classified under choline precursor. This index does not assert a combined effect. A compound supplying choline through metabolism. This biochemical relationship does not itself establish a cognitive outcome.

    Source 1 ↗
  • Editorial index: substances classified under age context. This index does not assert a combined effect. Age-defined study groups can differ in drug disposition. Age associations need study-specific interpretation.

    Source 1 ↗Source 2 ↗
  • Caffeine's adenosine antagonism connects a molecule, mechanism, transmitter system and functional class.

    Source 1 ↗
  • Age-group differences in one syrup study were not replicated in a lower-exposure experiment; no universal age multiplier is assigned.

    Source 1 ↗Source 2 ↗
  • Swine airway-cell assay; the result does not quantify human cognitive effects.

    Source 1 ↗
  • Tobacco-smoke exposure induces CYP1A2. The study measured declining caffeine clearance after cessation; enzyme activity decline is not caffeine elimination half-life.

    Source 1 ↗
  • Nicotine acts at nicotinic acetylcholine receptors; dependence is integral to the interpretation.

    Source 1 ↗
  • Fast-release melatonin with behavioral scheduling was studied in selected delayed sleep–wake phase disorder patients. The co-intervention is part of this relationship.

    Source 1 ↗
  • Conversion to circulating metabolites does not itself establish a cognitive benefit.

    Source 1 ↗
  • Repeated supplementation raised muscle total creatine concentration. Men receiving the studied supplementation protocols.

    Source 1 ↗
  • Creatine connects tissue energy metabolism and exercise research.

    Source 1 ↗
  • H1 antihistamine activity is distinct from the compound's antimuscarinic actions.

    Source 1 ↗
  • Secondary memory-task improvement in older adults with age-associated memory impairment; not a general memory claim.

    Source 1 ↗
  • Oral administration produced transporter occupancy in a human PET study.

    Source 1 ↗
  • Acute PET findings in healthy men; target occupancy is distinct from a clinical outcome.

    Source 1 ↗
  • Nicotine and caffeine have distinct major metabolic pathways; nicotine is not a proxy for tobacco smoke induction of CYP1A2.

    Source 1 ↗
  • Human antagonist studies link acute psilocybin effects to serotonin receptor signaling.

    Source 1 ↗
  • The sleep connection represents possible disruption, not a sleep benefit.

    Source 1 ↗
  • A small randomized study tested the combination. Co-study is not a recommendation to combine substances.

    Source 1 ↗
  • The higher-dose study arm reduced depression severity relative to the low-dose control at the primary time point. Treatment-resistant depression; standardized preparation and psychological support; assessment at week 3.

    Source 1 ↗
  • A scoped federal classification with an authority source; no inference about other jurisdictions.

    Source 1 ↗

Relationship nodes connect multiple concepts in one sourced statement. Member roles identify the substance, biological target, measured outcome, or exposure context. Editorial index relationships group classifications. Connections are not recommendations to combine substances.